Skip Navigation

Your Environment. Your Health.

Infliximab in Polymyositis and Dermatomyositis

Principal Investigator:

Mark Gourley, NIAMS, NIH

 

Study Design:

Phase 1-2, randomized, placebo controlled, cross-over trial. Infliximab dose 5-7.5 mg/kg, NIH only

 

Types & Number of IIM Studied:

Active Polymyositis and Dermatomyositis (N = 12)

 

Entry Criteria:

Probable or definite Bohan and Peter criteria for polymyositis or dermatomyositis, Refractory to methotrexate, azathioprine, or another immunosuppressive agent, as well as steroids

 

IMACS Core Set Measures Included:

All: Physician and Patient Global Activity Assessments, Manual Muscle Testing, enzymes, Health Assessment Questionnaire, Myositis Disease Activity Assessment Tool; Myositis Damage Index, Health-Related Quality of Life by SF-36

 

Other Measures Included:

Magnetic resonance imaging, flow cytometry, microarrays, cytokine levels/genes, MHC typing

 

Primary Outcome:

IMACS Definitions of Improvement and 15% increase of Manual Muscle Testing alone

 

Study Duration:

16 weeks treatment, placebo crossover to treatment for 16 weeks more with total duration 70 weeks

 

Funding:

NIAMS, NIH; Centocor

 

Comments:

Enrollment Completed

 

Contact:

Mark Gourley, M.D.
Tel (301) 451-6807
gourleym@mail.nih.gov
Paul Plotz, M.D.
Tel (301) 496-1474
plotzp@mail.nih.gov

 

Return to Therapeutic Studies listing

Back to Top